(Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...

Exforge Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure - Exforge offers two of the most prescribed high blood pressure medicines in a convenient ...

NEW YORK, Dec 28 (Reuters) - Novartis AG (NOVN.S), opens new tab said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in ...

EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...

Novartis has been boosted by data from a new study which shows that its new combination antihypertensive Exforge lowers blood pressure in twice as many patients than those on amlodipine alone.

Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The Swiss pharma will pay altogether $245 million in separate settlements with direct purchasers, ...

Deal is part of $245 million package announced last year Novartis, Endo unit accused of conspiring to keep competitors out Feb 23 (Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million ...

NEW YORK (Reuters) -Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic ...

NEW YORK, Dec 28 (Reuters) - Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of ...